JAK2 and myeloproliferative disorder: We found that JAK2 mutation as the disease driver gene is not as dominant in MPN–SC as compared with that seen in the control group (Figure 4A), suggesting that other genomic variations might play more significant roles in the disease course that potentially leads to the development of an SC.